Skip to content

Press Releases

May 30, 2019
Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
ANN ARBOR, Mich., May 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to welcome Tracy
May 28, 2019
Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., May 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: Jefferies Healthcare Conference in New York on Wednesday, June 5, 2019 at 8:30 a.m. E.T.
May 10, 2019
Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: Bank of America Merrill Lynch Healthcare Conference 2019 in Las Vegas on Tuesday, May 14, 2019 at
May 08, 2019
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019. “The potential of bempedoic acid is being broadly realized as evidenced by publication and
May 07, 2019
Esperion to Host Analyst and Investor Day Event on May 30
ANN ARBOR, Mich., May 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time. The event will feature presentations from members of the Esperion Lipid Management Team as
May 05, 2019
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
– Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver – – February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid and February 26, 2020 PDUFA Target Date Goal for the Bempedoic Acid / Ezetimibe Combination Tablet
Apr 02, 2019
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Apr 01, 2019
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
 –  Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant – –  Over 24-Weeks, Bempedoic Acid Was Observed to be Safe, Well-Tolerated, and the Muscle-Related Adverse Event Rate Did Not Differ from Placebo – –  Bempedoic
Mar 18, 2019
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
–Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP– –Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was Similar to that of Placebo– –Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor
Mar 13, 2019
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
–  Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – –  Bempedoic Acid is an Oral, Once-daily ATP Citrate
Mar 04, 2019
Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Mar 04, 2019
Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical trial session at the American College of
Feb 28, 2019
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Feb 28, 2019
Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications (NDAs) for bempedoic acid and the bempedoic acid / ezetimibe
Feb 22, 2019
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol